PHRM.O slid over 6 percent, also on Nasdaq. SPPI.O, which licensed the drug to GPC, were down over 23 percent on Nasdaq late in the session, while shares of Pharmion Corp. The company's shares fell 34 percent in German trading. Orplatna is the lead product candidate for Germany-based GPC Biotech. determination including substitute or supported decision-making and. Those findings are expected near the end of 2007. It was a suitable environment for creating new contacts, which in many cases grew into long-term business cooperation. The total number of new cases of dementia each year worldwide is nearly 7.7 million. The FDA will ask a panel of outside experts that meets Tuesday for input on those issues and whether officials should defer a decision on the drug until final survival data are available, the summary said. Prescriptive approach for people who want to think hard and systematically about decision problem Why Study Decision Analysis - Continued COMMENTS DECISION ANALYSIS: A DA is an information source Should not replace the decision maker but support him/her A DA does not only provide a solution, but also insight into Situation. The reviewers asked whether one of the main goals in a GPC study was an acceptable basis for approval, and if pain measurements were reliable, among other things. To make sure that the richness of the terrain is understood, we introduce the concepts of dynamic decision making, a. Thus, we talk about decisions to make, uncertain events, and valuing consequences. drug reviewers will ask an advisory panel whether they should wait for more data before deciding whether to approve GPC Biotech AG's GPCG.DE proposed prostate cancer pill, a summary released on Friday said.įood and Drug Administration staff raised five issues with GPC’s application for the drug Orplatna, known generically as satraplatin. This chapter is intended to start the reader thinking about decision problems in decision-analysis terms.
0 Comments
Leave a Reply. |